LTO1
Overview
LTO1 (also known as ORAOV1, oral cancer overexpressed 1) is located within the recurrent 11q13 amplicon in head and neck squamous cell carcinomas. It has been previously shown to promote tumor growth in OSCC and is co-amplified with CCND1 at this locus in a significant fraction of oral squamous cell carcinomas.
Alterations observed in the corpus
- Located within the 11q13 amplicon in OSCC; previously shown to promote tumor growth in OSCC; co-amplified with CCND1 (amplified in 22% of OSCC) and FADD, BIRC2, BIRC3, and IKBKB within this locus PMID:23619168
Cancer types (linked)
- OSCC (Oral Squamous Cell Carcinoma): copy number gain at 11q13; co-amplified with CCND1; previously shown to be functionally oncogenic in this cancer type PMID:23619168
Co-occurrence and mutual exclusivity
- Co-amplified with CCND1, FADD, BIRC2, BIRC3, and IKBKB at the 11q13 locus in HNSCC PMID:23619168
Therapeutic relevance
- No direct targeted therapy reported; potential co-driver at 11q13 amplicon; combined CCND1 amplicon targeting may need to account for LTO1 contribution PMID:23619168
Open questions
- Relative contribution of LTO1 versus CCND1 and other 11q13 co-amplified genes to OSCC oncogenesis is not individually quantified in this study PMID:23619168
Sources
This page was processed by crosslinker on 2026-05-09.